Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

← catalyst calendar

NCT04106219

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With New Approaches to Neuroblastoma Therapy Consortium, Innovative Therapies for Children with Cancer in Europe (ITCC).

Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
71estimated
Sites
17
Countries
Australia, Belgium, France +6

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2020-06-11actualWhen the study began enrolling
Primary completion2022-04-13actualThe date the last participant is measured for the primary outcome — the readout window
Study completionAug 2026estimatedThe whole study's end, after follow-up
First posted2019-09-26actualWhen this record first appeared on the registry
Results postedWhen the sponsor posted results to the registry
Record updated2026-04-21actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Neuroblastoma

Interventions

  • Drug: LY3295668 Erbumine
  • Drug: Topotecan
  • Drug: Cyclophosphamide

Primary outcomes

what the primary-completion date above is the date OF
Number of Participants with Dose Limiting Toxicities (DLTs)
measured Baseline through Cycle 2 (28 Day Cycle)
Overall Response Rate (ORR): Percentage of Participants Who Achieve Complete Response (CR) or Partial Response (PR)
measured Baseline through Measured Progressive Disease (Estimated up to 5 Years)
Duration of Response (DoR)
measured Date of CR or PR to Date of Disease Progression or Death Due to Any Cause (Estimated up to 5 Years)

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed